Ivonescimab Overview

Cooperative Binding Offers Potential to Drive Synergistic Activity1-3

Increased Avidity in TME3*

Enhanced Activity of T Cells3*
VEGF dimer leads to potential interconnection of ivonescimab molecules, which may increase activity of T cells

T1/2 ~10 days4 and Fc-null region3
Could potentially lead to a favorable safety profile

*in vitro

Images for illustrative purposes only.

VEGF Dimer icon

VEGF Dimer

PD-1 Receptor TCell

PD-1 Receptor in T Cell

Clinical Trials

For additional information on the HARMONi, HARMONi-3 or HARMONi-7 clinical trials, please visit clinicaltrials.gov or contact medinfo@smmttx.com

Phase 3 Study: NCT063960655

A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined with Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Have Progressed on or Following Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment.
Learn more.

HARMONi Fact Sheet

Phase 3 Study: NCT058996086

A Randomized, Double-blinded, Multiregional Phase 3 Study of ivonescimab Combined with Chemotherapy versus pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer.
Learn more.

HARMONi-3 Fact Sheet

Phase 3 Study: NCT067675147

A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression.
Learn more.

HARMONi-7 Fact Sheet

*There are no known PD-1-based bispecific antibodies approved by the U.S. Food and Drug Administration (“FDA”) or the European Medicines Agency (“EMA”).

Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA).

Abbreviations: EGFR mutant, epidermal growth factor receptor mutation; EGFR-TKI, epidermal growth factor receptor- tyrosine kinase inhibitor; PD-1, programmed death-1; PD-L1, programmed death-ligand 1; TME, tumor microenvironment; VEGF, vascular endothelial growth factor.

References:

  1. Zhao Y. et al., eClinicalMedicine. 2023; 3(62): 102106.;
  2. Wang L, et al. J Thorac Oncol. 2024 Mar;19(3):465-475;
  3. Zhong T, et al. iScience. 2024;28(3):111722.;
  4. Data on File 39. Summit Therapeutics Inc.
  1. HARMONi ClinicalTrials.gov identifier: NCT06396065. (Updated Oct 8.2024) 
  2. HARMONi-3 ClinicalTrials.gov identifier: NCT05899608. (Updated Mar 21.2025)
  3. HARMONi-7 ClinicalTrials.gov identifier: NCT06767514. (Updated Jan 10, 2025)

Ivonescimab is an investigational therapy not presently approved by any regulatory authority
other than China’s National Medical Products Administration (NMPA).